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Abstract Background Non-vitamin K oral anticoagulants
(NOACs) became available in the Netherlands in 2008,
providing another antithrombotic treatment besides vitamin
K antagonists (VKAs) and antiplatelet agents (APAs).
Objective To describe the patterns of antithrombotic drug
use between 2008 and 2013 by examination of dispensing
data form community pharmacies in the Netherlands; to
determine the concomitant use of NOACs with VKAs and
APAs and switching between the drug classes; and to
compare adherence to NOACs with adherence to APAs.
Setting An observational retrospective study was conducted
using routinely collected dispensing data from Dutch
community pharmacies. Methods For each calendar year,
the numbers of NOAC, VKA, and APA users were cal-
culated. Adherence was determined for NOACs and APAs
by the percentage of days covered by medication (PDC).
Information on the prescribed daily dose of VKAs was
unavailable. Main outcome measures Comparison of age,
sex, and co-medications of users of the three drug classes;
concomitant use of different antithrombotic drug classes
and switching between these in each year; and mean PDC
and percentages of all users with a PDC above 80 %. Re-
sults NOAC use increased during the study period to
29,687 users in 2013. In that year there were 484,024 VKA
users and 1313,032 APA users. Compared with users of
VKAs, NOAC users were slightly younger and more fre-
quently used antiarrhythmic drugs and beta blockers as co-
medications. Substantial numbers of patients were dis-
pensed potentially harmful combinations in 2013: 820
subjects were dispensed NOACs together with VKAs, and
684 subjects were dispensed NOACs, VKAs, and APAs
concomitantly. Mean adherence to NOACs was 84.2 %
compared with 87.3 % to APA. One in four NOAC users
had a PDC lower than 80 % compared with one in five
APA users. Conclusion Our findings show increasing use
of NOACs by outpatients. The number of patients taking
potentially harmful combinations of antithrombotic drugs
was substantial. Adherence to NOACs in daily practice
may be suboptimal to prevent thrombotic events.
Keywords Adherence  DOACs  Drug use patterns 
Netherlands  NOACs  Non-vitamin K oral anticoagulants
Impact of findings on practice
• Long-term use of NOACs increased markedly in out-
patients from 2008 to 2013.
• Substantial number of patients had potentially harmful
combinations of antithrombotic drugs.
• Adherence to NOACs determined from dispensing data
may be suboptimal to prevent thrombotic events.
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Introduction
Vitamin K antagonists (VKA) have been used as antico-
agulants for the past 70 years [1]. In the Netherlands
acenocoumarol and phenprocoumon are widely used,
whereas warfarin is most frequently used worldwide [2].
VKAs are highly effective in treating and preventing
thromboembolic events. However, they pose difficulties in
clinical practice as they have a narrow therapeutic range
and delayed onset or offset of effect. Furthermore, they
show a high dosage variation between individuals as well
as within subjects over time. This is related to various
factors such as age, body weight, genetic polymorphisms,
comorbidity, co-medication, dietary vitamin K intake, and
alcohol use [1, 3, 4]. Consequently VKA treatment has to
be monitored closely to ensure effective anticoagulation
without causing life-threatening bleeding. However, mon-
itoring is difficult in clinical practice. A recent meta-anal-
ysis in the United States showed that patients receiving
warfarin for stroke prevention were within the therapeutic
range only 55 % of the time [5]. These disadvantages
prompted the development of new oral anticoagulants with
a rapid onset of therapeutic effect and fewer drug interac-
tions [6, 7]. Furthermore, it is desirable that fixed doses can
be used without the need for constant coagulation moni-
toring [1, 8–11]. Among these new non-vitamin K oral
anticoagulants (NOACs), dabigatran specifically targets the
coagulation enzyme thrombin, whereas rivaroxaban and
apixaban inhibit factor Xa. In the Netherlands, dabigatran
and rivaroxaban were licensed in 2008 for prophylaxis of
venous thromboembolism in orthopaedic surgery for short-
term use up to 35 days after surgery [12, 13]. When their
effectiveness and safety were sufficiently proven in various
randomised controlled trials [14–18], marketing approval
of the NOACs was expanded in 2011 to prophylaxis for
embolism related to nonvalvular atrial fibrillation [12].
An important task for pharmacovigilance is themonitoring
of new drugs after their approval, including drug-related
problems such as potentially harmful drug combinations and
patient adherence. After NOACs were introduced as an
alternative to VKAs [19], some concerns regarding their use
were highlighted. First, while the effects of VKAs can be
reversed by vitamin K, there is currently no specific antidote
for the anticoagulant effects of NOACs [1, 10, 20]. Second,
because of their short half-lives, NOACs are less effective
when doses are missed [1]. Third, in the Netherlands, moni-
toring of VKAs is facilitated by a network of regional anti-
coagulation clinics that monitor about 400,000 VKA users
[21], and evidence suggests this improves the time spent in the
therapeutic range [5], and leads to cost savings [22, 23].
NOAC use is not monitored so closely. Fourth, although the
cited advantage of NOACs is that no routine monitoring is
required, knowledge of the precise anticoagulant status may
be needed in patients before emergency surgery or other
invasive procedures [6]. Little is known about NOAC use,
their use with other antithrombotic agents and adherence [8].
Aim of the study
The aims of this study were: to describe the patterns of use
of antithrombotic drugs, including NOACs, between 2008
and 2013 by examination of dispensing data from com-
munity pharmacies in the Netherlands; to determine the
concomitant use of NOACs with VKAs or antiplatelet
agents (APAs) and switching between the drug classes; and
to compare adherence to NOACs with adherence to APAs.
Ethical approval
Data of pharmacists and patients were coded and anonymised
prior to analysis. Use of observational data in descriptive
retrospective studies in theNetherlands is not considered as an
interventional trial according to Directive 2001/20/EC and to
Dutch legislation, and therefore does not need to be submitted
to a medical ethic committee for approval.
Methods
Setting
Patterns of drug use can be studied from pharmacy dis-
pensing data [24]. In the Netherlands, the Foundation of
Pharmaceutical Statistics (SFK) collected dispensing data
from 95 % of the 1981 Dutch community pharmacies in
2013 [25]. SFK data provide detailed information on the
drugs dispensed, including the codes from the Anatomic–
Therapeutic–Chemical (ATC) system of the World Health
Organization [26], the prescribed dose, and the amount
dispensed. Information on patient sex and year of birth was
available. The data did not provide information on clinical
diagnoses. Medication of a specific patient over time was
tracked within an individual pharmacy by a unique
anonymous code for each patient. Information on pre-
scribers was restricted to information on whether they were
a general practitioner (GP) or any medical specialist. Drug
exposure episodes were calculated by dividing the number
of drugs dispensed by the prescribed dose, except for
VKAs for which the dosing information was unavailable.
Study design
We performed an observational, retrospective cross-sec-
tional study stratified for each year between 2008 and 2013.
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Data of all users of a NOAC, VKA, or APA for each
calendar year were included.
Inclusion criteria
Data from all patients from Dutch community pharmacies
that had provided complete dispensing data for each year
and the preceding calendar year were collected. The latter
information was needed to define a first dispensing, as
described in the next paragraph. Patients were eligible
when they received at least one dispensing of a NOAC
(dabigatran, ATC code B01AE07, rivaroxaban B01AF01,
or apixaban B01AF02), a VKA (phenprocoumon B01A
A04 or acenocoumarol B01AA07), or an APA [acetylsal-
icylic acid (ASA) B01AC04, carbasalate calcium B01A
C06, dipyridamole B01AC08, clopidogrel B01AC04, pra-
sugrel B01AC22, or ticagrelor B01AC24].
Measures
The number of NOAC users was calculated per calendar
year, and stratified by short- and long-term use. Drug use
periods were calculated as the percentage of days covered
by medication (PDC) during a calendar year, based on
dispensings in that calendar year and within the 3 preced-
ing months. As information on diagnosis was not available,
short-term and long-term antithrombotic drug use had to be
distinguished in the dispensing data: subjects with a period
of continuous anticoagulant use of at least 35 days for
dabigatran and rivaroxaban and 38 days for apixaban were
regarded as being treated long term. The remaining NOAC
users were labelled as short-term users. The cutoffs of 35
and 38 days were chosen according to the guidelines for
treatment duration after hip and knee surgery [13].
Patient characteristics, numbers of drug users, and pro-
portions of co-medications and comorbidity were calcu-
lated for each antithrombotic drug class per calendar year.
A first dispensing of a particular antithrombotic was
defined by a dispensing without a dispensing of the cor-
responding antithrombotic drug class of NOACs, VKAs, or
APAs during the prior 12 months. Drug cessation was
defined as the absence of a refill prescription within 4
consecutive months. This threshold was chosen because in
the Netherlands a first prescription is supplied for 15 days
and each following prescription for 3 months. Co-medi-
cations had to be used chronically, defined as drug dis-
pensings covering at least 91 days during a calendar year.
With a normal drug supply of a maximum of 90 days per
dispensing, at least two dispensings of a drug class were
needed to meet this criterion. Episodes of drug use were
constructed with adjustments for early refills. Co-medica-
tion for treatment of cardiovascular diseases was defined as
chronic use of the following drug groups: statins (C10AA),
beta-blockers (C07A), antiarrhythmic I/III (C01B), calcium
channel antagonists (C08), thiazides (C03A, C03EA01),
loop diuretics (C03CA01, C03CA02), renin–angiotensin–
aldosterone system (RAAS) inhibitors (C09), aldosterone
antagonists (C03DA), digoxin (C01AA05). Two consecu-
tive nitrate dispensings (C01DA) were considered as a
proxy for angina pectoris. Concomitant use of a loop
diuretic (C03CA01 or C03CA02) and a RAAS inhibitor
(C09) were taken as a proxy for heart failure. To gain a
general insight into additional comorbidities, chronic
medication use was mapped for blood glucose-lowering
drugs (A10), thyroid drugs (H03), antidepressants (N06A),
anti-dementia drugs (N06D), antipsychotics (N05), drugs
for acid-related disorders (A02), drugs for asthma/chronic
obstructive pulmonary disease (R03), and drugs for treat-
ment of rheumatoid arthritis (A07EC01, L01AA01, L01C
B01, L01XC02, L04AA13, L04AA27, L04AB01, L04A
B02, L04AB04, L04AB05, L04AB06, L04AC03, L04AC
07, L04AD01, L04AX01, L04AX03, M01CB01, M01CC
01, P01BA01, P01BA02).
Concomitant use of NOACs and APAs (dual and triple
antithrombotic therapy) was determined by simultaneous
drug exposure for at least 91 days. Concomitant use of
VKAs, for which the prescribed daily dose was not avail-
able, was defined by at least two VKA dispensings within a
period of NOAC or APA use of at least 91 days. As
guidelines give explicit recommendations on the use of
combinations of acetylic salicylic acid (ASA) and other
antithrombotic drugs, the use of these drugs was shown
separately within the APA class.
Switchers from one antithrombotic drug class to another
were those subjects who started the use of another
antithrombotic drug class within a calendar year without
further dispensing of the antithrombotic drug class used
chronically previously.
Adherence to NOAC was compared with adherence to
APAs. Patients with only one NOAC or APA dispensing
detected in a pharmacy and without any other dispensings
during 2 calendar years were excluded (‘drop-in patients’).
Adherence was calculated from dispensing data as ‘drug-
taking adherence’ for long-term NOAC and APA users (see
definition for long-term use above). For each drug class,
the PDC was calculated from the first day of drug use until
the end of the calendar year. Mean percentages were
compared between both drug classes. In addition, the per-
centages of long-term users with a PDC higher than 80 %
within all long-term users were calculated for NOAC and
APA users.
Statistical analysis
Descriptive statistics were used for patient characteristics
and the use of antithrombotic drugs and co-medications.
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Patient characteristics and adherence measures were com-
pared by the Chi square test for dichotomous variables and
an independent t test for continuous variables. A p value
\0.05 was regarded as significant. Because of the inclusion
criteria, the proportion of community pharmacies con-
tributing data for the annual analysis varied between 73 %
in 2008 to 86 % in 2013 (Table 2). In order to show the
progression in the numbers of drug users between the study
years for Fig. 1 and Table 2, the absolute numbers were
standardised to the total number of Dutch community
pharmacies in that calendar year. Statistical analysis was
performed using IBM SPSS v.22.0 (IBM Corp., Armonk,
NY, USA).
Results
NOAC use increased from 18 patients in 2008 to 29,687 in
2013. Figure 1 shows the numbers of NOAC users during
the study period, stratified by short- and long-term use.
From 2011, the number of long-term users increased
steeply and exceeded short-term users in 2013. In com-
parison, the total number of VKA users in 2013 was
484,024 in the Netherlands. Table 1 compares the charac-
teristics of users of antithrombotic drug classes in 2013,
based on the data provided by 1697 community pharmacies
(86 % of the totally 1974 community pharmacies in the
Netherlands in that year). Thus NOAC users made up 6 %
of all users VKA users in 2013. NOAC users were slightly
younger than VKA users (mean age 70.3 vs. 73.5 years)
and used fewer co-medications, except for antiarrhythmic
drugs (used in 15.7 % of long-term NOAC users compared
with 7.8 % of VKA users) and beta blockers (used in
62.6 % of long-term NOAC users compared with 54.7 %
in VKA users). The majority (97 %) of NOAC users were
first prescribed a NOAC by a medical specialist, and 3 %
by a GP.
Table 2 shows the concomitant use of antithrombotic
drugs and switching between drug classes per calendar
year, with the absolute numbers standardized to the total
number of Dutch community pharmacies in the corre-
sponding calendar year. With the marked increase in
NOAC use, the number of users with concomitant use of
NOACs and other anticoagulants also increased. Although
the total number was proportionately small, the number of
patients was substantial: in 2013, a combination of NOACs
with VKAs was dispensed to 820 subjects (2.7 % of NOAC
users), while NOACs and ASA were dispensed to 446
subjects (1.5 % of NOAC users), compared with 11,207
receiving VKA and ASA (2.3 % of VKA users). Con-
comitant clopidogrel or prasugrel use occurred in 149
NOAC patients (0.5 % of NOAC users) compared with
concomitant use in 6822 VKA patients (1.4 % of VKA
users). Concomitant use of three antithrombotic drugs
(NOACs with ASA and clopidogrel or prasugrel) was
detected in 13 (0.05 %) patients, while 671 (0.1 %) VKA
users also used two APAs concomitantly. Switching to a
NOAC occurred more frequently than vice versa: 3502
subjects switched from a VKA to a NOAC, and 1552 from
a NOAC to a VKA; 4850 subjects switched from an APA
to a NOAC, and 2193 vice versa.
In 2013, the mean drug-taking compliance for NOACs
was 84.2 % compared with 87.3 % for APA (Table 3). The
percentage of subjects with a PDC higher than 80 % was
75.9 % for NOACs in chronic use compared with 80.2 %
for APAs.
Discussion
NOAC use in the Netherlands markedly increased during
the study period: in 2013 there were 29,687 NOAC users
compared to 484,024 VKA users. NOACs may be pre-
scribed as an alternative for patients who did not start with
VKAs because of the monitoring required, or for subjects
who could not achieve stable anticoagulation with VKA
treatment [27]. The latter reason is supported by the fact
that switching from a VKA to a NOAC occurred more than
twice as often as vice versa. Consistent with the guidelines,
NOAC treatment was predominantly initiated by medical
specialists and only occasionally by GPs. NOAC users
were slightly younger and differed in the use of co-medi-
cations. With growing NOAC use, the prevalence of
potentially harmful drug combinations increased: 820
subjects were detected in 2013 with concomitant use of
NOACs and VKAs, a non-rational and potentially risky
Fig. 1 Annual increase in the total number of for short- and long-
term NOAC users between 2008 and 2013. Annual numbers based on
community pharmacies with data available were standardised for the
total number of Dutch community pharmacies per year (see annual
numbers of pharmacies with data available and the total number in the
Netherlands at the bottom of Table 2)
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combination according to the guidelines [13]. Other com-
binations of antithrombotic drugs may have rational use for
a certain duration. To examine this further, longitudinal
research is needed together with information on dietary
intake and diagnosis [28].
Poor adherence has been shown to be the single most
important source of variations in the effects of all classes of
drug treatment [29]. In clinical practice persistence with
rivaroxaban was high in patients with atrial fibrillation
[30]. This study showed a discontinuation rate of 15 % in
the first year of treatment with rivaroxaban, mainly due to
bleeding complications and other side effects. Our analysis
shows that one in four NOAC users had a PDC lower than
80 % compared with one in five APA users. As we cal-
culated adherence rates only in subjects with periods of
NOAC use longer than for anticoagulation therapy in
orthopaedic surgery, we aimed to address patients on
lifelong NOAC therapy. Our strategy could either overes-
timate adherence (by falsely excluding early cessation in
lifelong therapy) or underestimate it (e.g., by falsely
Table 1 Characteristics of users of antithrombotic drug classes in 2013
NOAC VKA APA
Short-term users Long-term users All drug users All drug users
Number of users 10,794 14,727 416,104 1128,782
Male (%) 4560 (42.2) 8828 (59.9) 226,965 (54.5) 633,323 (56.1)
Mean age (±SDa) 69.1 (±10.6) 71.2 (±10.5) 73.5 (±13.2) 70.6 (±12.5)
First dispensing (%) 9915 (91.9) 8796 (59.7) nab 287,439 (25.5)
Cessation (%) 6101 (56.5) 2463 (16.7) 120,176 (28.9) 182,475 (16.2)
Medical specialist as first prescriber of drug (%) 10,403 96.4) 14,376(97.6) nab 29,216 (2.6)
Cardiac co-medication
Antiarrhythmics I/III (%) 359 (3.33) 2311 (15.7) 32,538 (7.8) 16,914 (1.5)
Statins (%) 1710 (15.8) 5455 (37.0) 163,789 (39.9) 674,613 (59.8)
Beta blockers (%) 2054 (19.0) 9218 (62.6) 227,432 (54.7) 509,047 (45.1)
Calcium channel antagonists (%) 972 (9.0) 3400 (23.1) 84,018 (20.2) 249,964 (22.1)
Thiazides (%) 711 (6.6) 1517 (10.3) 38,739 (9.3) 131,118 (11.6)
Loop diuretics (%) 394 (3.7) 2060 (14.0) 106,278 (25.5) 104,598 (9.3)
AAS inhibitors (%) 2161 (20.0) 7638 (51.9) 204,468 (49.1) 550,102 (48.7)
Concomitant use of loop diuretics and RAAS inhibitors (%) 424 (3.9) 1904 (12,9) 91,563 (22.0) 94,630 (8.4)
Aldosterone antagonists (%) 142 (1.3) 738 (5.0) 39,724 (9.6) 34,445 (3.1)
Digoxin (%) 188 (1.7) 1767 (12.0) 61,884 (14.9) 13,436 (1.2)
Two consecutive nitrate dispensings (%) 189 (1.78) 701 (4.76) 33,409 (8.03) 102,686 (9.10)
Non-cardiac co-medications
Blood glucose lowering agents (%) 704 (6.5) 2025 (13.8) 72,517 (17.4) 214,806 (19.0)
Antipsychotics (%) 622 (5.8) 1344 (9.1) 51,665 (12.4) 133,602 (11.8)
Drugs for acid-related disorders (%) 1942 (18.0) 4911 (33.3) 147,229 (35.4) 488,212 (43.3)
Drugs for asthma or COPD (%) 724 (6.7) 1830 (12,4) 66,947 (16.1) 155,822 (13.8)
Drugs for rheumatoid arthritis (%) 108 (1,0) 172 (1.2) 6759 (1.6) 16,799 (1.5)
Antidepressants (%) 456 (4.2) 831 (5.6) 30,157 (7.3) 98,964 (8.8)
Antithyroid drugs (%) 396 (3.7) 787 (5.3) 26,372 (6.3) 63,605 (5.6)
Numbers were based on data of 1697 Dutch community pharmacies, 86 % of all Dutch community pharmacies in 2013 (The absolute numbers of
NOAC users as presented in Fig. 1 and Table 2 were standardised to the total number of all Dutch community pharmacies per calendar year:
25.521 NOAC users from the 1697 community pharmacies that provided data on 2013 vs 29.687 NOAC users standardised to all 1974 Dutch
community pharmacies in 2013)
Differences between all users of drug classes were compared for strata of patient characteristics, co-medications and comorbidity. Differences
between numbers of NOAC, APA and VKA users were statistically significant for all parameters (p value\ 0.01)
NOAC non-vitamin K oral anticoagulants, VKA vitamin K antagonists, APA antiplatelet agents, RAAS renin–angiotensin–aldosterone system,
COPD chronic obstructive pulmonary disease
a Standard deviation
b Not applicable, information not available in the data
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including physician-initiated discontinuations because of
major bleeding) [7]. The cut-off for adherence of a PDC of
80 % was chosen according to published studies [31].
However, this might be too low for NOACs which have
short half-lives of between 7 and 17 h, and where there is a
greater impact of a missed dose in achieving steady anti-
coagulation compared with VKAs [1, 7]. Consequently, a
smaller proportion of NOAC users than VKA users may
achieve effective anticoagulation in clinical practice. The
impact of adherence to NOACs on clinical outcomes in
daily practice is not known as yet [7, 32]. It was suggested
that the advantage of NOACs in not requiring regular
laboratory monitoring may translate into a lower awareness
of the need to assess adherence [32]. Thus NOACs may not
be suitable replacements for VKA in patients with adher-
ence issues [1, 33]. Comparisons of adherence to VKAs
and NOACs in clinical trials showed comparable poor
results for both drug classes [14–16]. However, in a review
of a healthcare claims database in Canada, rivaroxaban was
associated with a significantly lower risk of nonadherence
compared with warfarin (hazard ratio for cessation = 0.66)
[34]. This could be different from the situation in
Netherlands because of the therapeutic VKA monitoring by
specialised anticoagulation clinics [35]. To ensure an
optimal antithrombotic effect, continuous and regular
intake of NOACs is necessary [32, 33]. A number of bar-
riers to optimal NOAC use have been identified, such as a
lack of knowledge of stroke risk on the one hand side and
of bleeding risk on the other [36]. A combination of
strategies from prescribers and pharmacists was proposed
to provide tailored support for optimal use of NOACs [32,
37]. Consequently, prescribers and pharmacists should
address adherence to NOACs during each patient consul-
tation [33]. Pharmacists can contribute to better adherence
[33] and have been shown to improve adherence by use of
dispensing data to detect patients who did not return for
their medication in time [31].
A limitation of estimating adherence from dispensing
data is the lack of information on when doses were taken or
missed [7]. Thus our results could overestimate adherence
in daily practice, especially when the temporal sequence of
the doses is essential in delivering stable anticoagulation by
a drug with a short half-life of 8 to 11 h [38]. Another
shortcoming of our study was the lack of information on
Table 2 Numbers of concomitant users of and switchers between antithrombotic drug classes
2008 2009 2010 2011 2012 2013
Concomitant users of NOAC and VKAb 0 23 27 32.9 760 820
Concomitant usersa of NOAC and ASA 0 7 13 19.5 248 446
Concomitant usersa of NOAC and clopidogrel/prasugrel 0 0 3 6 81 149
Concomitant usersa of ASA and VKAb 11,738 12,300 12,927 12,862 12,559 11,207
Concomitant usersa of clopidogrel/prasugrel and VKAb 4737 5444 6322 7106 6730 6822
Concomitant usersa of NOAC, ASA and clopidogrel/prasugrel 0 0 0 0 15 13
Concomitant usersa of ASA, clopidogrel/prasugrel and VKAb 717 805 973 1088 1111 671
Switchers from NOAC to VKA 0 50 127 170 946 1552
Switchers from VKA to NOAC 0 304 120 305 3570 3502
Switchers from NOAC to APA 0 284 777 978 2077 2139
Switchers from APA to NOAC 1 456 797 1154 4078 4850
Switchers from VKA to APA 33,828 37,364 39,348 40,755 40,803 38,471
Switchers from APA to VKA 42,694 44,575 47,955 54,092 53,690 51,820
Total number of NOAC users 18 3280 7287 9662 22,009 29,687
Total number of VKA users 417,964 428,073 438,572 458,107 470,527 484,024
Total number of APA users 1263,266 1287,046 1209,941 1335,651 1324,743 1313,032
Number of Dutch community pharmacies with available
data (% of all community pharmacies)
1415
(72.6)
1530
(77.4)
1557
(78.6)
1637
(82.0)
1720
(86.8)
1697
(86.0)
Total number of Dutch community pharmacies 1948
(100)
1976
(100)
1980
(100)
1997
(100)
1981
(100)
1974
(100)
Patient numbers in available data were standardised to the total number of community pharmacies per calendar year for NOAC, VKA, and APA
ASA acetyl salicylic acid, PDC percentage of days covered by medication during a calendar year
a Concomitant use of the drug groups for at least 91 days
b As the PDC could not be calculated for VKA, concomitant use with VKA is assumed for two VKA dispensings within at least 91 days of
concomitant use of NOACs or APAs
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the indication for prescribing the drugs. In order to dis-
tinguish between short- and long-term use, we used periods
of drug use with cutoff points as given in the current
guidelines, but this may have introduced some misclassi-
fication. However, as we used the same criteria for APAs to
compare adherence, this is unlikely to have caused differ-
ential misclassification. A further shortcoming of our study
was that we could not compare NOAC adherence with
VKA adherence because of the lack of information on
individual VKA dosages in the pharmacy data. Therefore,
adherence to APAs was chosen as the best alternative for
an antithrombotic drug class. The validity of dispensing
data for calculating adherence measures depends on the
loyalty of patients to the same pharmacy. In the Nether-
lands, pharmacy-shopping behaviour is low [39], and fur-
thermore we excluded ‘drop-in’ patients. Finally, our cross-
sectional study design for a comprehensive description of
annual NOAC use since their introduction into the market
did not allow us to evaluate the duration of antithrombotic
treatment at the patient level over time to assess the
duration of specific antithrombotic therapy and combina-
tions. A strength of our study was the availability of
national dispensing data, which enabled us to describe the
use of antithrombotic drugs in the Netherlands in the past 5
calendar years.
Conclusion
Our findings show amarked increase in the use of NOACs by
outpatients in recent years in the Netherlands. The study
indicated that a substantial number of patients require
additional management to improve the safe and effective use
of NOACs in clinical practice, with a reduction in non-ra-
tional combinations of antithrombotic drugs, and improved
adherence.
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